Saudi Arabia-Pharmaceutical Market Growth, Trends and Forecast


Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs. The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators.

Browse Full Report With TOC:

Headline Expenditure Projections

Pharmaceuticals: SAR16.70bn (US$4.46bn) in 2011 to SAR18.95bn (US$5.06bn) in 2012; +13.5% in local currency and US dollar terms. Forecastbroadly unchanged from Q3 12.

Healthcare: SAR78.63bn (US$21.00bn) in 2011 to SAR91.20bn (US$24.35bn) in 2012; +16.0% in local currency and US dollar terms. Forecast broadly unchanged from Q3 12.

Medicaldevices: SAR5.54bn (US$1.48bn) in 2011 to SAR6.53bn (US$1.74bn) in 2012; +17.8% in local currency and US dollar terms. Forecastunchanged from Q3 12.

Risk/Reward Rating

Saudi Arabia's composite score remained steady in Q4 12 at 55.6. This places the country to firth place out of the 30 markets in the region. Its score is propped up by the country's wealth and a sizeable population (exceeding 28mn in 2011). Furthermore, its forecast growth rate is high due to favourable public and private healthcare investments. The government is also in the process of creating more public-private health partnerships and encouraging private health insurance uptake, which should provide momentum for drug sales.

To Get Download Full Report with TOC:

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.


Table of Contents

Executive Summary7

SWOT Analysis9

Saudi Arabia Pharmaceuticals And Healthcare SWOT9

Saudi Arabia Political SWOT10

Saudi Arabia Economic SWOT10

Saudi Arabia Business Environment SWOT11

Pharmaceutical Risk/Reward Ratings12

Table: Middle East And Africa Pharmaceutical Risk/Reward Ratings, Q21312



Saudi Arabia - Market Summary16

To Read Complete Report with TOC:

Regulatory Regime18

Regulatory Developments19

Regional Regulatory Developments20

Free Trade Agreements21

Intellectual Property Regime21

IP Deficiencies23

Counterfeit Drugs25

OTC Drug Market25

Pricing Regime25

Reimbursement Regime26

Pricing System Reform26


About Us is the most comprehensive collection of market research reports. services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact US:

Office: United States

State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
Tel: +1-518-618-1030